Molecular genetics of solid tumours: translating research into clinical practice. What we could do now: breast cancer.
Breast cancer is a common solid malignancy in women. Over the past decade, much progress has been made in understanding the biology of breast cancer. The use of molecular and immunohistochemical techniques is providing insights that will allow us to tailor the management of patients with breast cancer. In this review, progress in the understanding of lobular carcinoma in situ and atypical ductal hyperplasia, the use of the molecular marker CerbB2, and information gained from the morphological analysis of tumours arising in patients with BRCA1 and BRCA2 mutations is discussed.
Lakhani
S R
SR
The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, Mary-Jean Mitchell Green Building, Chester Beatty Laboratories, Fulham Road, London SW3 6JB, UK. lakhani@icr.ac.uk
D024682:BRCA2 Protein / Q000235:genetics; D014408:Biomarkers, Tumor / Q000032:analysis; D001940:Breast / Q000473:pathology; D001943:Breast Neoplasms / Q000235:genetics* / Q000378:metabolism; D002278:Carcinoma in Situ / Q000235:genetics / Q000378:metabolism; D018275:Carcinoma, Lobular / Q000235:genetics / Q000378:metabolism; D019317:Evidence-Based Medicine; D005260:Female; D019398:Genes, BRCA1; D006801:Humans; D006965:Hyperplasia / Q000235:genetics / Q000378:metabolism; D008967:Molecular Biology; D009154:Mutation / Q000235:genetics; D011230:Precancerous Conditions / Q000235:genetics / Q000378:metabolism; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis
D024682:BRCA2 Protein; D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases